This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
by Zacks Equity Research
Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.
Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
by Christopher Vargas
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $66.19 in the latest trading session, marking a -1.88% move from the prior day.
Court Ruling Topples Trump Order, No Price Display in TV Ads
by Zacks Equity Research
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Will Patent Woes Boost Pharma Stock Megamergers Further?
by Nilanjan Banerjee
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status
by Zacks Equity Research
Glaxo's (GSK) long-acting, injectable two-drug regimen gets FDA's priority review designation. The company begins study to identify approaches to implementing once-monthly injectable HIV treatment in the real world.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $69 in the latest trading session, marking a +0.23% move from the prior day.
Gilead to Submit NDA for Inflammation Drug Filgotinib in '19
by Zacks Equity Research
Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.
Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer
by Zacks Equity Research
Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.
Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation
by Zacks Equity Research
Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Alexion Receives FDA Approval for Label Expansion of Soliris
by Zacks Equity Research
Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $67.08 in the latest trading session, marking a +0.6% move from the prior day.
Zacks Market Edge Highlights: Facebook, Gilead, Disney, Grubhub and Microsoft
by Zacks Equity Research
Zacks Market Edge Highlights: Facebook, Gilead, Disney, Grubhub and Microsoft
Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.
5 Game Changing M&A Deals of the Last Decade
by Tracey Ryniec
M&A deals are usually ignored, or sometimes even openly mocked, but it can lead to an earnings and revenue renaissance. Did you spot these?
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
by Zacks Equity Research
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $69.38 in the latest trading session, marking a +1.18% move from the prior day.
3 Big Biotechs Hold Growth Potential in Second Half of 2019
by Ekta Bagri
We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
by Zacks Equity Research
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
by Zacks Equity Research
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Big Drugmakers That May Tread the M&A Path After Pfizer
by Kinjel Shah
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
by Zacks Equity Research
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
GILD vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?